CAR T-cell therapy in pediatric oncology: From leukemia to emerging promise in Wilms tumor and solid malignancies
Topic overview
This article explores CAR T-cell therapy's evolution in pediatric cancer treatment, from its groundbreaking success in acute lymphoblastic leukemia to its expanding application in solid tumors including Wilms tumor. The piece traces the technology's development from first-generation CARs in the early 1990s through FDA approval and clinical implementation, highlighting its role as a personalized immunotherapeutic approach in childhood malignancies.
Key takeaways
- CAR T-cell therapy genetically modifies patient T cells to target cancer, providing personalized treatment in pediatric oncology.
- Second-generation CARs (early 2000s) showed enhanced efficacy over first-generation designs from 1989-1993.
- FDA-approved CAR T achieved first pediatric complete remission in ALL in 2013, establishing proof of concept.
- Technology evolved from 1980s immunotherapy research to clinical application over three decades of development.
- CAR T shows emerging promise beyond leukemia, with potential applications in Wilms tumor and other solid malignancies.
Keywords
Hashtags
Full article text
Full article text not available for this entry
How to cite: GlobalCastMD. CAR T-cell therapy in pediatric oncology: From leukemia to emerging promise in Wilms tumor and solid malignancies. GlobalCastMD Medical Library. 2025-08-28. https://library.globalcastmd.com/article/10911
Comments